Bagsværd, Denmark, 7 May 2019 - Novo Nordisk A/S has today entered into an
agreement to purchase 7,012,500 B shares of DKK 0.20 to a value of DKK 2,235
million from Novo Holdings A/S. This transaction is part of Novo Nordisk A/S'
2019 share repurchase programme of up to a total of DKK 15 billion to be
executed during a 12-month period beginning 1 February 2019. The transaction
price is DKK 318.71 per share and has been calculated as the three-day volume
weighted average market price from 3 May to 7 May 2019 in the open window
following the announcement of Novo Nordisk A/S' quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S' ownership of Novo Nordisk A/S
was 28.6% of the share capital and 76.3% of the votes. Following the
transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and
142,776,500 B shares of DKK 0.20, corresponding to 28.3% of the capital and
76.2% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement on 3 May 2019 that Novo
Holdings A/S intends to maintain its ownership of Novo Nordisk A/S' share
capital around 28%.
With the transaction stated above, Novo Nordisk A/S owns a total of 22,369,001 B
shares of DKK 0.20, corresponding to 0.9% of the share capital, as treasury
shares. The total amount of A and B shares in the company is 2,400,000,000 of
DKK 0.20 including treasury shares.
About Novo Holdings A/S
Novo Holdings is a Danish private limited liability company wholly owned by the
Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising
Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the
In addition to being the major shareholder in the Novo Group companies, Novo
Holdings provides seed and venture capital to development-stage companies, takes
significant ownership positions in well-established companies within life
science and manages a broad portfolio of financial assets.
It is the vision of Novo Holdings to be recognized as a world-leading life
science investor with a focus on creating long-term value. Read more
About Novo Nordisk A/S
Novo Nordisk is a global healthcare company with more than 95 years of
innovation and leadership in diabetes care. This heritage has given us
experience and capabilities that also enable us to help people defeat obesity,
haemophilia, growth disorders and other serious chronic diseases. Headquartered
in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and
markets its products in more than 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter,
Novo Holdings Communication
Christian Mostrup Scheel +45 3067 4805 email@example.com
Novo Nordisk Media:
Anne Margrethe Hauge +45 4442 3450 firstname.lastname@example.org
Ken Inchausti (US) +1 609 240 9429 email@example.com
Novo Nordisk Investors:
Peter Hugreffe Ankersen +45 3075 9085 firstname.lastname@example.org
Valdemar Borum Svarrer +45 3079 0301 email@example.com
Ann Søndermølle Rendbæk +45 3075 2253 firstname.lastname@example.org
Kristoffer Due Berg (US) +1 609 235 2989 email@example.com
Company announcement No 31/2019
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
© InPublic, source European Press Releases